Richard Valicenti, M.D., M.A., FASTRO
Philosophy of Care
Dr. Valicenti believes in being tough on cancer, using a multi-disciplinary team approach and
leading therapeutic weapons to maximize outcomes while preventing side effects. He emphasizes
that innovation is critical to the advancement of new cancer treatments and that education is
essential for the benefit of patients, families and the next generation of cancer caregivers.
Clinical Interests
Dr. Valicenti is nationally and internationally recognized in the treatment of prostate cancer and
other tumors. His clinical interests focus on prostate cancer, gynecologic tumors, genitourinary
malignancies and brain tumors. He is also interested in the use of prostate seed implantation and
Gamma Knife for cancer treatment.
Research/Academic Interests
Dr. Valicenti is conducting clinical research to evaluate multi-modality therapies for clinically
localized prostate cancer. In addition, he is carrying out outcome-based studies addressing qualityof-life questions and exploratory analyses of large databases.
Title
Professor, Department of Radiation Oncology
Specialty
Prostate Cancer, Radiation Oncology, Cancer
Department
Radiation Oncology
Division
Radiation Oncology
Clinic
Center/Program Affiliation
Address/Phone
UC Davis Cancer Center
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center, 4501 X St. G-140 Sacramento, CA 95817
Phone: 800-362-5566
Additional Phone
Fax: 916-703-5069
Clinic Phone: 916-703-5820
Physician Referrals: 800-362-5566
Languages
Education
German, Italian
M.D., Drexel University College of Medicine, Philadelphia PA 1990
M.A., Columbia University Graduate School, New York NY 1984
B.S., Massachusetts Institute of Technology (MIT), Cambridge MA 1981
Internships
Internal Medicine, Hahneman Hospital, Philadelphia PA 1991
Richard Valicenti, M.D., M.A., FASTRO
Residency
Radiation Oncology, Washington University School of Medicine, St. Louis MO 1995
Fellowships
Radiation Oncology, Washington University School of Medicine, St. Louis MO 1995
Board Certifications
Professional Memberships
American Board of Radiology, Radiation Oncology, 2006
American Society of Clinical Oncology
American Society of Therapeutic Radiology and Oncology
Honors and Awards
Best Doctors in America, Radiation Oncology, 2005-2013
Resident Travel Award, American Society of Therapeutic Radiology and Oncology (Faculty
Advisor), 2006
Sigma Xi Award for Medical Student Research (Faculty Advisor), 2006
Resident Clinical Research Award, American Society of Therapeutic Radiology and Oncology
(Faculty Advisor), 2003
Marquis Who's Who in Medicine, 2002
Philadelphia Magazine, Best Docs, Radiation Oncology, 2002
Select Recent Publications
Rash, DL, Lee, YC, Kashefi, A, Durbin-Johnson, B, Mathai, M, Valicenti, R, Mayadev, JS. Clinical
response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive
management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2013;87(2): 317-22.
Lim, J, Durbin-Johnson, B, Valicenti, R, Mathai, M, Stern, RL, Mayadev, J, ,. The impact of
maximum rectal distention and tandem angle on rectal dose delivered in 3D planned gynecologic
high dose-rate brachytherapy. Int. J. Gynecol. Cancer. 2013;23(6): 1078-83.
Rash, D, Hagar, Y, Cui, J, Hunt, JP, Valicenti, R, Mayadev, J, ,. Interfraction motion of the vaginal
apex during postoperative intensity modulated radiation therapy: are we missing the target? Int. J.
Gynecol. Cancer. 2013;23(2): 385-92.
Kunos, CA, Winter, K, Dicker, AP, Small, W, Abdul-Karim, FW, Dawson, D, Jhingran, A,
Valicenti, R, Weidhaas, JB, Gaffney, DK. Ribonucleotide reductase expression in cervical cancer: a
radiation therapy oncology group translational science analysis. Int. J. Gynecol. Cancer. 2013;23
Richard Valicenti, M.D., M.A., FASTRO
(4): 615-21.
Lim, J, Durbin-Johnson, B, Valicenti, R, Mathai, M, Stern, RL, Mayadev, J. The impact of body
mass index on rectal dose in locally advanced cervical cancer treated with high-dose-rate
brachytherapy. Brachytherapy. 2013;12(6): 550-4.
Valicenti, RK, Thompson, I, Albertsen, P, Davis, BJ, Goldenberg, SL, Wolf, JS, Sartor, O, Klein, E,
Hahn, C, Michalski, J, Roach, M, Faraday, MM, ,. Adjuvant and salvage radiation therapy after
prostatectomy: American Society for Radiation Oncology/American Urological Association
guidelines. (ASTRO/AUA Joint Approved Publication). Int J Radiat Oncol Biol Phys. 2013;86(5):
822-8.
Thompson, IM, Valicenti, RK, Albertsen, P, Davis, BJ, Goldenberg, SL, Hahn, C, Klein, E,
Michalski, J, Roach, M, Sartor, O, Wolf, JS, Faraday, MM. Adjuvant and salvage radiotherapy after
prostatectomy: AUA/ASTRO Guideline. (ASTRO/AUA Joint Approved Publication). The Journal of
Urology. 2013;190(2): 441-9.
Greene, DE, Mayadev, JS, Valicenti, RK. Radiation treatment for patients with intermediate-risk
prostate cancer. Therapeutic Advances in Urology. 2012;4(3): 113-24.
Michalski, J, Winter, K, Roach, M, Markoe, A, Sandler, HM, Ryu, J, Parliament, M, Purdy, JA,
Valicenti, RK, Cox, JD. Clinical Outcome of Patients Treated With 3D Conformal Radiation
Therapy (3D-CRT) for Prostate Cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012;83(3):
e363-70.
Perks JR, Stanic S, Stern RL, Henk B, Nelson MS, Harse RD, Mathai M, Purdy JA, Valicenti RK,
Siefkin AD, Chen AM. Failure Mode and Effect Analysis for Delivery of Lung Stereotactic Body
Radiation Therapy. Int J Radiat Oncol Biol Phys. 2011 Dec 22. [Epub ahead of print]
Stanic S, Mathai M, Cui J, Purdy JA, Valicenti RK. Relationship Between Pelvic Organ-at-Risk Dose
Richard Valicenti, M.D., M.A., FASTRO
and Clinical Target Volume in Postprostatectomy Patients Receiving Intensity-Modulated
Radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 30. [Epub ahead of print]
Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J. Does hormone therapy
reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An
analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79
(5):1323-9.
Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. A Phase I trial of samarium153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first
report of a completed study. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):732-7. Epub 2010
Apr 14.
© 2016 UC Regents